AKINETON SUMMARY
AKINETON® Tablets
(biperiden hydrochloride)
Each AKINETON tablet for oral administration contains 2 mg biperiden hydrochloride. Other ingredients may include corn syrup, lactose, magnesium stearate, potato starch and talc. AKINETON is an anticholinergic agent. Biperiden is α-5-Norbornen-2-yl-α-phenyl-1-piperidinepropanol. It is a white, crystalline, odorless powder, slightly soluble in water and alcohol. It is stable in air at normal temperatures.
AKINETON (biperiden) is indicated for the following:
- As an adjunct in the therapy of all forms of parkinsonism (idiopathic, postencephalitic, arteriosclerotic)
- Control of extrapyramidal disorders secondary to neuroleptic drug therapy (e.g., phenothiazines)
|
NEWS HIGHLIGHTS
Published Studies Related to Akineton (Biperiden)
Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. [2010.06]
BACKGROUND: Clozapine-induced sialorrhea (CIS) is a subjective distressing adverse effect and occurs in 31%-57% of schizophrenic patients receiving clozapine therapy. Current pharmacotherapy on CIS has focused on anticholinergic agents, even though they may impair cognitive function. Previous case reports have suggested the benefit of glycopyrrolate or biperiden in treating this condition, but no randomized controlled trial has provided evidence. The objective of our study was to evaluate the efficacy and impact on cognition of glycopyrrolate and biperiden treatments for schizophrenic patients suffering from CIS... CONCLUSION: We provide evidence, for the first time, of the efficacy of glycopyrrolate and biperiden in the treatment of CIS. Furthermore, glycopyrrolate displays less impact on cognitive function. Consequently, glycopyrrolate can become a valid option for treating CIS. Observations from our study serve as a springboard for additional large-scale prospective trials. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects. [2005.09]
RATIONALE: The central cholinergic system is implicated in cognitive functioning. The dysfunction of this system is expressed in many diseases like Alzheimer's disease, dementia of Lewy body, Parkinson's disease and vascular dementia. In recent animal studies, it was found that selective cholinergic modulation affects visuospatial processes even more than memory function. OBJECTIVE: In the current study, we tried to replicate those findings. In order to investigate the acute effects of cholinergic drugs on memory and visuospatial functions, a selective anticholinergic drug, biperiden, was compared to a selective acetylcholinesterase-inhibiting drug, rivastigmine, in healthy elderly subjects... CONCLUSIONS: These results implicate acetylcholine as a modulator not only of memory but also of visuospatial abilities.
A comparison of scopolamine and biperiden as a rodent model for cholinergic cognitive impairment. [2011.06]
CONCLUSION: Muscarinic m1 antagonists should be considered an interesting alternative for SCOP as a pharmacological model for cholinergic mnemonic deficits in animals.
Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. [2011.01.15]
BACKGROUND: The high use of long-term antiparkinsonian anticholinergic drugs with antipsychotics has been identified as an important issue in the treatment of schizophrenia in Japan. The aim of this study was to evaluate the effects of gradual discontinuation of biperiden, an anticholinergic drug, on cognitive function and quality of life (QOL) in schizophrenia... CONCLUSION: Discontinuation of long-term biperiden use may be warranted in patients with schizophrenia treated with SGAs, as it may improve cognitive function, subjective QOL, and psychiatric symptoms with no significant adverse effects. Crown Copyright (c) 2010. Published by Elsevier Inc. All rights reserved.
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions. [2008.12.03]
The effects of biperiden (0, 100, and 320 microg/kg), a selective muscarinic M(1)/M(4) receptor cholinergic antagonist, were studied alone and in combination with those of L-DOPA methyl ester (16.7 mg/kg), a selective dopamine D(1) receptor agonist SKF-82958 (74.8 microg/kg), or a selective D(2)/D(3) receptor agonist rotigotine (32 microg/kg) on circling behavior in MPTP induced hemiparkinsonian monkeys...
Clinical Trials Related to Akineton (Biperiden)
Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence [Recruiting]
The aim of this study is to assess the efficacy of caffeine compared to placebo as a
maintenance treatment for cocaine dependence. Caffeine potentiation with biperiden will be
also studied.
Ninety patients with snorted/sniffed cocaine dependence will be randomized to receive
caffeine (300 - 1200 mg t. i.d.) plus biperidene (8 mg b. i.d.) caffeine (300 - 1200 mg
t. i.d.) with placebo or placebo during 10 days in an in-hospital setting.
Cocaine/Crack and Reduction of Compulsion With Biperiden [Recruiting]
Cocaine consumption affects around 13. 4 mi people or 0. 3% of the world population between 15
and 64 years old. The drug dependence has been described by many authors as a dysfunction of
the brain reward system. Considering the effects of the cholinergic system on the drug
reward and self-administration mechanisms, acetylcholine (Ach) may play an important role on
cocaine dependence process. Then the present study aims to evaluate biperiden efficacy (a
cholinergic antagonist) in attenuate compulsion, one o the main symptoms of the drug
dependence. To accomplish this purpose 60 cocaine or crack male users between 18 and 50
years old will be study. This is a double-blind controlled and randomized placebo study. All
the patients will be treated with brief intervention therapy (BIT), and half of them will
receive biperiden (6mg/day) while the other half will receive placebo. The treatment
efficacy will be evaluated through the comparison between the values obtained on the
following measures before and after the treatment: Craving scale of Minnesota and
Cocaine/crack consumption questionnaire, and the presence of the cocaine metabolite
(benzoylecgonine) on urine.
Use of Biperiden for the Prevention of Post-traumatic Epilepsy [Not yet recruiting]
There is no AED or medication that has been demonstrated to affect the development of post
traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic
receptor, that is widely used as an anti Parkinson drug. The investigators data with animal
models of epilepsy indicate that anti-muscarinic agents might affect the natural course of
the disease in the case of post traumatic epilepsy.
Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients [Recruiting]
The aim of this study is to assess the efficacy of caffeine compared to placebo in
detoxifying cocaine dependent patients. Caffeine potentiation with biperiden will be also
studied.
108 with cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t. i.d.) plus biperidene (8 mg b. i.d.) or caffeine (300 - 1200 mg t. i.d.) with placebo or placebo
during 6 months.
Primary efficacy outcomes will be 1) patient comfort assessed with abstinence
symptomatology, craving for cocaine and mental status during detoxifying period, 2) study
retention and 3) cocaine use.
Brain dopamine system will be assessed thru IBZM-SPECT and the apomorphine test.
Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD) [Not yet recruiting]
This study was designed to evaluate the pharmacokinetic profile, safety and efficacy in
Parkinson's Disease patients.
|
